In this model, combination of CDK6 inhibitor palbociclib with lenvatinib showed the maximal suppression of tumor growth, warranting evaluation of this combination in clinical trials with TKI-resistant advanced HCC patients [85]. Here, CDK6 is linked to hepatocellular carcinoma.